Purpose/Objective: Verification of the calculated and delivered dose trough independent verification of treatment planning system (TPS) and in vivo dosimetry are important part of the overall radiotherapy quality assurance (QA). The verification of TPS was done according to IAEA recommendations and put an emphasis on dosimetry part of the treatment planning and delivery processes. In vivo dosimetry was implemented as quality assurance procedure for patient treatment verification. Materials and Methods: Verification of TPS was done with anthropomorphic phantom which was later also used for in vivo measurements prior to patient measurements. Set of clinical test cases suggested by the IAEA, covering a range of typical clinical radiation techniques found in 3D conformal radiotherapy treatment (3D CRT) was used both for TPS and in vivo dosimetry verification. The doses were measured with ion chamber and semiconductor diodes, and compared to doses calculated in TPS for interest points for test cases and points in build up for entrance in vivo readings. Consequently, set of breast patients were checked by in vivo during their regular treatments. For patient treatment verification, tangential half fields were used and in vivo diodes were placed off axis, under large gantry angles, with different wedge types and angles. Results: The measurements were conducted for 6 MV beam energy and advanced calculation algorithm. The differences between the measured and calculated doses for all test cases were within the tolerance level. The differences of in vivo phantom measurements and TPS calculation varied depending on the test type: 0.5% for open field case to 5.3% for enhanced dynamic wedge (EDW) test case. In vivo measurements conducted for breast patients showed difference of not more than 5% in comparison with values calculated by TPS. Conclusions: After verification of TPS calculation, dose calibration and correction factors for semiconductor diodes were checked and prediction for in vivo doses in TPS was verified. The errors of 5 % magnitude are common in clinics worldwide and clinical implementation of in vivo dosimetry in our clinic has given confidence that patients are being treated with prescribed dose. This was opportunity to systematically review the uncertainties involved in treatment planning and dose delivery processes leading to more accurate patient treatment. Acknowledgement: The work has been supported by IAEA through the national SRB6006 and regional RER 6023 technical cooperation project. 
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Purpose/Objective: We investigate how QA criteria relate to sensitivity end specificity for increased normal tissue toxicity risk and risk of decreased tumour control in rotational therapy for prostate cancer. Materials and Methods: QA analysis for 8 clinical plans and 160 plans with deliberately introduced errors was carried out using ten sets of QA criteria. The tumour control probability (TCP), and risk of rectal bleeding (NTCP_rectum), were calculated. An unacceptable plan was defined as a plan where TCP decreased by more than 2%, or the NTCP increased by more than 50%, as compared with the clinical plan. We chose the 50% NTCP threshold as the rectum was in the low dose region. The sensitivity and specificity for detecting unacceptable plans and their sum (S+S) were determined for each QA criteria set. The diagnostic quality of the QA criteria was also assessed by receiver-operator characteristics curves. For dose difference (DD) = 3 % and distance to agreement (DTA) = 3 mm; the required percentage of gamma smaller than 1 for acceptance (A) was scanned and the value of A which maximised S+S was determined. In an iterative process TCP and TNCP respectively were varied to find the values which corresponded to DD=3%, DTA =3 mm and A = 95 %. Results: A set of DD = 3 %; DTA = 3 mm and A = 95 % corresponds to ensuring that TCP is > 99 %; and NTCP < 160%; of the clinical values. For DD = 3 %; DTA = 3 mm, S+S was maximised for A = 95 %. We could not identify a single set of QA parameters that was significantly better than the others. However, three of the criteria had a significantly lower area under the ROC curve than the best parameter sets.
Conclusions:
A method for relating clinical risk estimates to QA parameters has been demonstrated. This method can be used to determine A for given DD and DTA values once the relative weights of sensitivity and specificity have been chosen by the user. It can also be used to determine which values of ΔTCP and ΔNTCP correspond to the chosen QA criteria set. Purpose/Objective: To assess the accuracy of a three-dimensional dose verification technique for patient-specific Quality Assurance (QA) in active scanning proton therapy. Critical cases of major deviations between treatment planning system (TPS) calculated and measured data points are further investigated with Monte Carlo (MC) simulations. Materials and Methods: Treatment plan verification is performed in a water phantom with the simultaneous use of twelve small-volume ionization chambers (one data set), aligned in four rows in a way that none of them perturbs the other ones. The acceptance threshold is set at 5% for both mean deviation between measured and calculated doses and one standard deviation, over twelve measurement points. Results of 180 data sets, obtained along one year of clinical activity at the Italian National Center for Oncological Hadron Therapy (CNAO), were analyzed.Data were organized based on tumor site (skull versus sacrum) and TPS optimization technique (single field uniform dose SFUD versus intensity modulated particle therapy IMPT). A warning level was defined for data sets showing more than 30% of single point absolute deviations higher than 5% and needing further investigation. A MC tool for plan verification in water was implemented to evaluate the impact of dose calculation, dose delivery and measurement set-up uncertainties on the nine cases resulting out of the warning level. Results: All patient-specific quality checks resulted within the acceptance threshold. Mean deviation between TPS dose calculation and measurement was less than ±3% in 86%of the cases. For targets located in the skull region an average higher deviation was found, compared to the sacrum region, due to more complex dose patterns involved. In addition, the use of a less robust optimization technique, such as IMPT compared to SFUD, produced much more scattered results and higher single point variation. When all sources of uncertainty were accounted for with the MC tool, all the simulated cases showed even higher level of agreement, with mean absolute deviation ≤ 2% (maximum absolute deviation< 5%). Conclusions: Along this first year of clinical activity, the results of all patient-specific QA checks performed using ICs in a 3D configuration were found within the acceptance threshold. The use of a MC-based tool to investigate potential causes of major deviations should be further explored, particularly for more complex IMPT plans.
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Optimization of VMAT patient specific QA using ImatriXX 2-D array system and ionometric point dose measurements J. Kunnanchath For applications which operate near the limits of machine capabilities and tolerance doses, such as hypo fractionated volumetric modulated arc therapy (VMAT), dose volume histogram (DVH) based analysis is preferred. The purpose of this work is to present the principles of a DVH based QA technique using radiochromic film in a cylindrical phantom.
Materials and Methods
1.
A VMAT plan was created for a lung patient with a commercial treatment planning system (Varian Eclipse). Commonly such plans consist of a clock wise and a counter clockwise 360 degree arc. Using the proposed technique requires that each field be split into two 180 degree arcs so that we can acquire the entrance and exit doses simultaneously on gafchromic film (ISP EBT3) surrounding a cylindrical phantom at Dmax.
2.
A Verification Plan (VP) is created in Eclipse for both the patient and the phantom. Note that VP has the ability to modify several plan parameters such as Monitor Units (MU), Micro Leaf Collimator positions, and arc angles corresponding to the plan control points. This capability has not been presented or exploited in any previous work. 3.
The MUs for one control point in the patient VP were modified to represent possible delivery error. The plan was delivered to the phantom on a Varian TrueBeam Linac and the film processed according to the manufacturers recommendations using only the red color component.
4.
Comparison of the planned phantom dose (PPD) and the actual measured phantom dose (MPD) in is performed in MATLAB with the imaging toolbox. Algorithms compute the gantry angle, field size, and the ratio of the measured to plan dose for any modified control points. 5.
The measured control point modifications were incorporated back into the patient VP and an updated modified patient dose distribution computed. DVH tools in Eclipse are used for comparison of the original patient plan and modified patient plan. Note that all calculations are performed within the same treatment planning system thereby avoiding differences due to calculation algorithms. Results: Experimental studies show that changes in a single control point such as shown in Figure 1 can be detected and they can lead to significant clinical changes, including maximum dose to a critical organ. The detail in Figure 1 is sufficient to resolve 2.5 mm MLC leaves. The observed intensity pattern differs slightly from the expected dose of a single control point. Further investigation is required to see if this is due to leaf motion during rotation between control points. Figure 1 . Conclusions: We have described a QA technique for DVH comparison of a computed patient plan with the actual delivered plan using a commercial treatment planning system and measurements with radiochromic film in a cylindrical phantom. Purpose/Objective: We investigated a commercial system, consisting of the ArcCHECK (AC) dosimeter and 3DVH (Version 2.2, Sun Nuclear Corp). This combination allows reconstructing 3D patient dose based on measurements. The objective of this work is to study the behaviour of the Planned Dose Perturbation (ACPDP) algorithm and to investigate its accuracy under different basic situations. Materials and Methods: In our scenario the phantom is considered as the patient, allowing independent measurements. To investigate the performance of ACPDP we introduced three kinds of 'errors' into simple reference plans. It was then examined whether ACPDP could reproduce the dose of the modified plan, using the (non-modified) reference plan as a-priori knowledge and the AC measurements of the modified plan. The errors introduced into a homogenous static field were (a) an over-dosage (1 to 5%) in areas of different size, and (b) a variation of the MLC field width (±2 to ±8 mm). The error (c) was introduced into a dynamic arc field (90° to 270°) simulating a deviation of MLC position (±2 to ±10 mm) of 1/3 of the leaves. All measurements were performed on a Varian CLINAC 2100CD, dose calculation in Eclipse (TPS: AAA 10.0.28). Ion chamber (IC) and EBT3 film were used to establish the TPS as a very accurate reference. Results: TPS dose calculation agreed very well with IC (-0.4 to 0.6%) and selected AC diodes (-0.8 to 1.3%). Relative film measurements confirmed the very accurate TPS calculation of gradients at field edges. Error (a) could clearly be found in the dose reconstructed by 3DVH (agreement within ±0.5%) as long as the 'High Sensitivity' (HS) mode of the ACPDP algorithm was used and the area was larger then 1x1 cm². The error was ignored for smaller areas and with ACPDP in 'Normal Sensitivity' (NS) mode. The deviation (b) was clearly recognized by the AC diodes. Still, almost no influence of the measurements could be seen at the field edge in the ACPDPcalculated dose (HS) based on those measurements. The error was either ignored completely or an unrealistic interpolation between expected and measured dose was performed (Fig. 1a) . Error (c) extends the results of (b). Again, although the error was measured, ACPDP-calculated dose (HS) shows increasing deviations from the expected dose with increasing error. The effect is more pronounced in the periphery where the differences exceed 3% for a 2 mm MLC displacement and go up to more than 15% for 10 mm. The agreement in the phantom centre was better, ranging from 0.8 to 2.9% (Fig. 1b) .
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